The recent verdict in a Risperdal-related case may have tipped the ongoing mass-tort litigation in the plaintiffs’ favor, but attorneys are not expecting a global settlement any time soon.
A Philadelphia jury Monday awarded plaintiff Nicholas Murray $1.75 million on claims that the antipsychotic drug Risperdal caused gynecomastia, a condition in which boys grow excessive breast tissue. Murray, who has Asperger’s syndrome, had been prescribed the drug for his attention deficit hyperactivity disorder.
